Business
Pro Medicus (ASX:PME) share price drops lower despite FDA approval
The Pro Medicus Limited (ASX: PME) share price is dropping lower on Tuesday despite the release of a positive announcement this morning.
At the time of writing, the leading health imaging company’s shares are down 1% to $42.39.
What did Pro Medicus announce?
This morning the company announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its Breast Density artificial intelligence (AI) algorithm.
This means the company now has clearance in the US, Europe, and Australia markets, which paves the way for management to begin marketing the algorithm across all three jurisdictions.
What does this algorithm do?
According to the release, the Breast Density algorithm is intended for use with compatible…
-
General21 hours agoThousands join pro-Palestinian rallies in towns and cities across Australia amid ceasefire
-
General21 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test
-
General19 hours agoBathurst 1000 quick hits: Chaz Mostert drinks beer with fans, Erebus owner protests, and drama on Mount Panorama
-
Noosa News18 hours agoFatal Traffic Crash, South Bingera